Zusammenfassung
Die medikamentenresistente Tuberkulose („drug-resistant tuberculosis“ [DR-TB]) ist auf globalem Niveau eines der größten Probleme bei der effektiven Bekämpfung der Tuberkulose. Dieser Übersichtsbeitrag beschreibt in Kürze die globale Epidemiologie, Diagnostik und Behandlung der DR-TB. Detailliert wird auf die Situation in Deutschland, der Schweiz und Österreich eingegangen. Eine Vorstellung der aktuellen Forschungsschwerpunkte im Bereich der resistenten Tuberkulose schließt den Beitrag ab.
Abstract
Drug-resistant tuberculosis (DR-TB) is one of the serious problems in the fight against tuberculosis on a global scale. This review article describes in brief the global epidemiology, diagnostics and treatment of DR-TB. The situation in Germany, Switzerland and Austria is addressed in detail. The article concludes with a presentation of current research topics in the field of resistant TB.
Literatur
Bundesministerium für Gesundheit (2013) Infektionsschutzgesetz vom 20. Juli 2000 (BGBl. I S. 1045), zuletzt geändert durch Artikel 2 Absatz 36 u. Artikel 4 Absatz 21 des Gesetzes vom 7. August 2013 (BGBl. I S. 3154). http://www.bgbl.de/xaver/bgbl/start.xav%3Fstart=%2F%2F*%5B%40attr%5Fid%3D%27bgbl111s1622.pdf%27%5D%23%5F%5Fbgbl%5F%5F%2F%2F*%5B%40attr%5Fid%3D%27bgbl111s1622.pdf%27%5D%5F%5F1444312936681. Zugegriffen: 08.10.2015
Kompetenzzentrum Tuberkulose Lungenliga. www.tbinfo.ch. Zugegriffen: 08.10.2015
Österreichische Agentur für Gesundheit und Ernährungssicherheit (AGES) http://www.ages.at. Zugegriffen: 08.10.2015
Österreichische Agentur für Gesundheit und Ernährungssicherheit (AGES), Institut für medizinische Mikrobiologie und Hygiene Wien, Nationale Referenzzentrale für Tuberkulose Jahresbericht 2013. http://www.ages.at/fileadmin/AGES2015/Themen/Krankheitserreger_Dateien/Tuberkulose/Tuberkulose_Jahresbericht_2013.pdf. Zugegriffen: 08.10.2015
Österreichische Gesellschaft für Antimikrobielle Chemotherapie Infektionen. Meldepflichtige Krankheiten in Österreich. www.infektionsnetz.at/TextExtMeldepflicht.phtml. Zugegriffen: 08.10.2015
Republic of South Africa’s Department of Health (2011) Management of drug-resistant tuberculosis. policy guidelines, august 2011. http://www.hst.org.za/publications/management-drug-resistant-tuberculosis-policy-guidelines. Zugegriffen: 08.10.2015
Robert Koch Institut www.rki.de. Zugegriffen: 08.10.2015
Robert Koch Institut Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2013. http://www.rki.de/DE/Content/InfAZ/T/Tuberkulose/Download/TB2013.pdf?__blob=publicationFile. Zugegriffen: 08.10.2015
Schweizerische Eidgenossenschaft - Bundesamt für Gesundheit BAG www.bag.admin.ch. Zugegriffen: 08.10.2015
Schweizerische Eidgenossenschaft - Der Bundesrat Verordnung über die Meldung übertragbarer Krankheiten des Menschen. https://www.admin.ch/opc/de/classified-compilation/19983529. Zugegriffen: 08.10.2015
World Health Organization Updated interim critical concentrations for first-line and second-line DST (as of may 2012). http://www.stoptb.org/wg/gli/assets/documents/Updated%20critical%20concentration%20table_1st%20and%202nd%20line%20drugs.pdf. Zugegriffen: 08.10.2015
World Health Organization (2014) Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. http://apps.who.int/iris/bitstream/10665/130918/1/9789241548809_eng.pdf. Zugegriffen: 08.10.2015
World Health Organization (2011) Guidelines for the programmatic management of drug-resistant tuberculosis. http://apps.who.int/iris/bitstream/10665/44597/1/9789241501583_eng.pdf. Zugegriffen: 08.10.2015
Aung KJ, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, Rieder HL (2014) Successful ‚9-month Bangladesh regimen‘ for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 18:1180–1187
Belard S, Heuvelings CC, Janssen S, Grobusch MP (2015) Bedaquiline for the treatment of drug-resistant tuberculosis. Expert Rev Anti Infect Ther 13:535–553
Belard S, Janssen S, Osbak KK, Adegnika AA, Ondounda M, Grobusch MP (2015) Limited access to drugs for resistant tuberculosis: a call to action. J Public Health 37(4):691–693
Borgdorff MW, van Soolingen D (2013) The re-emergence of tuberculosis: what have we learnt from molecular epidemiology? Clin Microbiol Infect 19:889–901
Brown M, Varia H, Bassett P, Davidson RN, Wall R, Pasvol G (2007) Prospective study of sputum induction, gastric washing, and bronchoalveolar lavage for the diagnosis of pulmonary tuberculosis in patients who are unable to expectorate. Clin Infect Dis 44:1415–1420
Cremers AL, de Laat MM, Kapata N, Gerrets R, Klipstein-Grobusch K, Grobusch MP (2015) Assessing the consequences of stigma for tuberculosis patients in urban Zambia. PLOS One 10:e0119861
Diacon AH, Pym A, Grobusch MP, de Los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paepe E, van Heeswijk RP, Dannemann B (2014) Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 371:723–732
Diel R, Nienhaus A, Lampenius N, Rusch-Gerdes S, Richter E (2014) Cost of multi drug resistance tuberculosis in Germany. Respir Med 108:1677–1687
Drobniewski F, Cooke M, Jordan J, Casali N, Mugwagwa T, Broda A, Townsend C, Sivaramakrishnan A, Green N, Jit M, Lipman M, Lord J, White PJ, Abubakar I (2015) Systematic review, meta-analysis and economic modelling of molecular diagnostic tests for antibiotic resistance in tuberculosis. Health Technol Assess 19:1–188
Gimmi R, Pfyffer GE, Brändli O (2003) Multiresistente Tuberkulose – in der Schweiz heilbar. Schweiz Med Forum 4:80–90
Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD (2012) Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 366:2151–2160
Lawn SD, Meintjes G, McIlleron H, Harries AD, Wood R (2013) Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review. BMC Med 11:253
Lewis JM, Sloan DJ (2015) The role of delamanid in the treatment of drug-resistant tuberculosis. Ther Clin Risk Manag 11:779–791
Madansein R, Parida S, Padayatchi N, Singh N, Master I, Naidu K, Zumla A, Maeurer M (2015) Surgical treatment of complications of pulmonary tuberculosis, including drug-resistant tuberculosis. Int J Infect Dis 32:61–67
Marais BJ, Mlambo CK, Rastogi N, Zozio T, Duse AG, Victor TC, Marais E, Warren RM (2013) Epidemic spread of multidrug-resistant tuberculosis in Johannesburg, South Africa. J Clin Microbiol 51:1818–1825
Marais E, Mlambo CK, Lewis JJ, Rastogi N, Zozio T, Grobusch MP, Duse A, Victor T, Warren RW (2014) Treatment outcomes of multidrug-resistant tuberculosis patients in Gauteng, South Africa. Infection 42:405–413
McNerney R, Maeurer M, Abubakar I, Marais B, McHugh TD, Ford N, Weyer K, Lawn S, Grobusch MP, Memish Z, Squire SB, Pantaleo G, Chakaya J, Casenghi M, Migliori GB, Mwaba P, Zijenah L, Hoelscher M, Cox H, Swaminathan S, Kim PS, Schito M, Harari A, Bates M, Schwank S, O’Grady J, Pletschette M, Ditui L, Atun R, Zumla A (2012) Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis 205(Suppl 2):S147–S158
Nkosi D, Janssen S, Padanilam X, Louw R, Menezes CN, Grobusch MP (2013) Factors influencing specialist care referral of multidrug- and extensively drug-resistant tuberculosis patients in Gauteng/South Africa: a descriptive questionnaire-based study. BMC Health Serv Res 13:268
Nunn AJ, Rusen ID, Van Deun A, Torrea G, Phillips PP, Chiang CY, Squire SB, Madan J, Meredith SK (2014) Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials 15:353
Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, Metcalfe JZ, Cattamanchi A, Dowdy DW, Dheda K, Banaei N (2014) Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev 27:3–20
Parida SK, Axelsson-Robertson R, Rao MV, Singh N, Master I, Lutckii A, Keshavjee S, Andersson J, Zumla A, Maeurer M (2015) Totally drug-resistant tuberculosis and adjunct therapies. J Intern Med 277:388–405
Richter E, Rusch-Gerdes S, Hillemann D (2009) Drug-susceptibility testing in TB: current status and future prospects. Expert Rev Respir Med 3:497–510
Steingart KR, Jotblad S, Robsky K, Deck D, Hopewell PC, Huang D, Nahid P (2011) Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 15:305–316
van Altena R, de Vries G, Haar CH, de Lange WC, Magis-Escurra C, van den Hof S, van Soolingen D, Boeree MJ, van der Werf TS (2015) Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000–2009. Int J Tuberc Lung Dis 19:406–412
Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL (2010) Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 182:684–692
Wallis RS, Kim P, Cole S, Hanna D, Andrade BB, Maeurer M, Schito M, Zumla A (2013) Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet 13:362–372
Walzl G, Haks MC, Joosten SA, Kleynhans L, Ronacher K, Ottenhoff TH (2014) Clinical immunology and multiplex biomarkers of human tuberculosis. Cold Spring Harb Perspect Med 5(4). doi:10.1101/cshperspect.a018515
Wejse C (2015) Tuberculosis elimination in the post millennium development goals era. Int J Infect Dis 32:152–155
Wells WA, Boehme CC, Cobelens FG, Daniels C, Dowdy D, Gardiner E, Gheuens J, Kim P, Kimerling ME, Kreiswirth B, Lienhardt C, Mdluli K, Pai M, Perkins MD, Peter T, Zignol M, Zumla A, Schito M (2013) Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infect Dis 13:449–458
World Health Organization (2014) WHO Global TB report 2014
Zar HJ, Hanslo D, Apolles P, Swingler G, Hussey G (2005) Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study. Lancet 365:130–134
Zhang X, Falagas ME, Vardakas KZ, Wang R, Qin R, Wang J, Liu Y (2015) Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis 7:603–615
Ziegler R, Just HM, Castell S, Diel R, Gastmeier P, Haas W, Hauer B, Loytved G, Mielke M, Moser I, Nienhaus A, Richter E, Ruden H, Rusch-Gerdes S, Schaberg T, Wischnewski N, Loddenkemper R (2012) Tuberculosis infection control – recommendations of the DZK. Pneumologie 66:269–282
Zumla A, Chakaya J, Centis R, D’Ambrosio L, Mwaba P, Bates M, Kapata N, Nyirenda T, Chanda D, Mfinanga S, Hoelscher M, Maeurer M, Migliori GB (2015) Tuberculosis treatment and management – an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet 3:220–234
Zumla A, Chakaya J, Hoelscher M, Ntoumi F, Rustomjee R, Vilaplana C, Yeboah-Manu D, Rasolof V, Munderi P, Singh N, Aklillu E, Padayatchi N, Macete E, Kapata N, Mulenga M, Kibiki G, Mfinanga S, Nyirenda T, Maboko L, Garcia-Basteiro A, Rakotosamimanana N, Bates M, Mwaba P, Reither K, Gagneux S, Edwards S, Mfinanga E, Abdulla S, Cardona PJ, Russell JB, Gant V, Noursadeghi M, Elkington P, Bonnet M, Menendez C, Dieye TN, Diarra B, Maiga A, Aseffa A, Parida S, Wejse C, Petersen E, Kaleebu P, Oliver M, Craig G, Corrah T, Tientcheu L, Antonio M, Rao M, McHugh TD, Sheikh A, Ippolito G, Ramjee G, Kaufmann SH, Churchyard G, Steyn A, Grobusch M, Sanne I, Martinson N, Madansein R, Wilkinson RJ, Mayosi B, Schito M, Wallis RS, Maeurer M (2015) Towards host-directed therapies for tuberculosis. Nat Rev 14:511–512
Zumla A, Maeurer M (2015) Host-directed therapies for tackling multi-drug resistant tuberculosis: learning from the pasteur-Bechamp debate. Clin Infect Dis: (Jul 28. pii: civ631. Epub ahead of print)
Danksagung
Wir danken Herrn Peter Helbling (BAG) und Herrn Prof. Dr. Otto Schoch (Lungenliga Schweiz) für die freundliche Unterstützung bei der Erstellung des Manuskripts.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
F. Schaumburg, E. Altpeter und S. Bélard geben an, dass kein Interessenkonflikt besteht. M.P. Grobusch weist auf folgende Beziehung hin: M.P. Grobusch ist Mitglied des wissenschaftlichen Beirats für Bedaquilin (Janssen) und Delamanid (Otsuka).
Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Additional information
Redaktion
B. Salzberger, Regensburg
T. Welte, Hannover
Rights and permissions
About this article
Cite this article
Grobusch, M.P., Schaumburg, F., Altpeter, E. et al. Medikamentenresistente Tuberkulose. Internist 57, 126–135 (2016). https://doi.org/10.1007/s00108-015-0010-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00108-015-0010-x